2023
The Role of Vascular Biomarkers in Outcomes of Patients with Kidney Disease
Shi A, Mansour S. The Role of Vascular Biomarkers in Outcomes of Patients with Kidney Disease. Nephron 2023, 147: 778-781. PMID: 37611550, PMCID: PMC10841333, DOI: 10.1159/000533415.Peer-Reviewed Original ResearchConceptsAcute kidney injuryAngpt-2 levelsCardiovascular diseaseVascular biomarkersPoor outcomeChronic kidney disease patientsPoor long-term outcomesGrowth factorKidney transplant recipientsOutcomes of patientsKidney disease progressionKidney disease patientsLong-term outcomesPlacental growth factorVascular endothelial growth factorEndothelial growth factorAKI patientsAKI survivorsCardiac complicationsKidney injuryTransplant recipientsCardiac surgeryHeart failureHospitalized patientsEndothelial damage
2022
Plasma Soluble Tumor Necrosis Factor Receptor Concentrations and Clinical Events After Hospitalization: Findings From the ASSESS-AKI and ARID Studies
Coca SG, Vasquez-Rios G, Mansour SG, Moledina DG, Thiessen-Philbrook H, Wurfel MM, Bhatraju P, Himmelfarb J, Siew E, Garg AX, Hsu CY, Liu KD, Kimmel PL, Chinchilli VM, Kaufman JS, Wilson M, Banks RE, Packington R, McCole E, Kurth MJ, Richardson C, Go AS, Selby NM, Parikh CR. Plasma Soluble Tumor Necrosis Factor Receptor Concentrations and Clinical Events After Hospitalization: Findings From the ASSESS-AKI and ARID Studies. American Journal Of Kidney Diseases 2022, 81: 190-200. PMID: 36108888, PMCID: PMC9868060, DOI: 10.1053/j.ajkd.2022.08.007.Peer-Reviewed Original ResearchConceptsSoluble tumor necrosis factor receptor 1Acute kidney injuryHeart failureClinical eventsIndex hospitalizationPlasma soluble tumour necrosis factor receptor 1Soluble tumour necrosis factor receptor concentrationsBiomarker measurementsKidney disease incidenceBaseline serum samplesKidney disease progressionLate heart failureTumor necrosis factor receptor 1Association of biomarkersProportional hazards modelNecrosis factor receptor 1Magnitude of associationFactor receptor 1AKI statusIndex admissionKidney eventsKidney outcomesAKI definitionKidney injuryHospital dischargeAngiopoietins as Prognostic Markers for Future Kidney Disease and Heart Failure Events after Acute Kidney Injury
Mansour SG, Bhatraju PK, Coca SG, Obeid W, Wilson FP, Stanaway IB, Jia Y, Thiessen-Philbrook H, Go AS, Ikizler TA, Siew ED, Chinchilli VM, Hsu CY, Garg AX, Reeves WB, Liu KD, Kimmel PL, Kaufman JS, Wurfel MM, Himmelfarb J, Parikh SM, Parikh CR. Angiopoietins as Prognostic Markers for Future Kidney Disease and Heart Failure Events after Acute Kidney Injury. Journal Of The American Society Of Nephrology 2022, 33: 613-627. PMID: 35017169, PMCID: PMC8975075, DOI: 10.1681/asn.2021060757.Peer-Reviewed Original ResearchConceptsCKD progressionHeart failureLower riskAngpt-1Highest quartileFuture kidney diseaseSetting of AKIAcute kidney injuryHeart failure admissionsHeart failure eventsProspective cohort studyMortality 3 monthsPlasma angiopoietinsKidney injuryCohort studySecondary outcomesEndothelial injuryMedian agePrimary outcomeKidney diseasePrognostic markerAngiopoietin-2AKIAngiopoietin-1Vessel destabilization
2019
Association of plasma-soluble ST2 and galectin-3 with cardiovascular events and mortality following cardiac surgery
Patel DM, Thiessen-Philbrook H, Brown JR, McArthur E, Moledina DG, Mansour SG, Shlipak MG, Koyner JL, Kavsak P, Whitlock RP, Everett AD, Malenka DJ, Garg AX, Coca SG, Parikh CR. Association of plasma-soluble ST2 and galectin-3 with cardiovascular events and mortality following cardiac surgery. American Heart Journal 2019, 220: 253-263. PMID: 31911262, PMCID: PMC7008086, DOI: 10.1016/j.ahj.2019.11.014.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAgedBiomarkersBlood ProteinsCardiac Surgical ProceduresCardiovascular DiseasesCause of DeathCohort StudiesCoronary Artery BypassFemaleGalectin 3GalectinsHeart Valve Prosthesis ImplantationHumansInterleukin-1 Receptor-Like 1 ProteinMalePostoperative ComplicationsProspective StudiesVentricular RemodelingConceptsGal-3 levelsCardiovascular eventsCardiac surgerySignificant post-operative morbidityGalectin-3Gal-3 valuesPlasma soluble ST2Composite primary outcomePrimary composite outcomePost-operative morbidityCongestive heart failurePost-operative changesPotential clinical utilityRandom-effects modelPlasma sST2Soluble suppressionComposite outcomeHazard ratioProspective cohortTumorigenicity 2Heart failurePrimary outcomeMyocardial remodelingClinical covariatesClinical utility